These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 18959599)

  • 61. GIP analogues and the treatment of obesity-diabetes.
    Bailey CJ
    Peptides; 2020 Mar; 125():170202. PubMed ID: 31756366
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature.
    Chrysavgis LG; Kazanas S; Bafa K; Rozani S; Koloutsou ME; Cholongitas E
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612640
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The incretin system and its role in type 2 diabetes mellitus.
    Holst JJ; Vilsbøll T; Deacon CF
    Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery.
    Martinussen C; Veedfald S; Dirksen C; Bojsen-Møller KN; Svane MS; Wewer Albrechtsen NJ; van Hall G; Kristiansen VB; Fenger M; Holst JJ; Madsbad S
    Am J Physiol Endocrinol Metab; 2020 Jun; 318(6):E956-E964. PubMed ID: 32182123
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Different incretin responses after pancreatoduodenectomy and distal pancreatectomy.
    Mori Y; Ohtsuka T; Tsutsumi K; Yasui T; Ueda J; Takahata S; Nakamura M; Tanaka M
    Pancreas; 2012 Apr; 41(3):455-60. PubMed ID: 22422137
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cellular mechanisms of incretin hormone secretion.
    Santos-Hernández M; Reimann F; Gribble FM
    J Mol Endocrinol; 2024 May; 72(4):. PubMed ID: 38240302
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
    Diamant M; Bunck MC; Heine RJ
    Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Interplay between bone and incretin hormones: A review.
    Mabilleau G
    Morphologie; 2017 Mar; 101(332):9-18. PubMed ID: 27423214
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Fasting and oral glucose-stimulated levels of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are highly familial traits.
    Gjesing AP; Ekstrøm CT; Eiberg H; Urhammer SA; Holst JJ; Pedersen O; Hansen T
    Diabetologia; 2012 May; 55(5):1338-45. PubMed ID: 22349073
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions.
    Girard J
    Diabetes Metab; 2008 Dec; 34(6 Pt 1):550-9. PubMed ID: 19036624
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Chronic high-fat feeding increases GIP and GLP-1 secretion without altering body weight.
    Wang F; Yoder SM; Yang Q; Kohan AB; Kindel TL; Wang J; Tso P
    Am J Physiol Gastrointest Liver Physiol; 2015 Nov; 309(10):G807-15. PubMed ID: 26336929
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Incretins and other peptides in the treatment of diabetes.
    Todd JF; Bloom SR
    Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Roux-en-Y gastric bypass versus calorie restriction: support for surgery per se as the direct contributor to altered responses of insulin and incretins to a mixed meal.
    Berggren J; Lindqvist A; Hedenbro J; Groop L; Wierup N
    Surg Obes Relat Dis; 2017 Feb; 13(2):234-242. PubMed ID: 27894746
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of different sweet preloads on incretin hormone secretion, gastric emptying, and postprandial glycemia in healthy humans.
    Wu T; Zhao BR; Bound MJ; Checklin HL; Bellon M; Little TJ; Young RL; Jones KL; Horowitz M; Rayner CK
    Am J Clin Nutr; 2012 Jan; 95(1):78-83. PubMed ID: 22158727
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Measurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide.
    Kuhre RE; Wewer Albrechtsen NJ; Hartmann B; Deacon CF; Holst JJ
    J Diabetes Complications; 2015 Apr; 29(3):445-50. PubMed ID: 25623632
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1?
    Holst JJ
    BioDrugs; 2002; 16(3):175-81. PubMed ID: 12102645
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?
    Meier JJ; Nauck MA
    Diabetes; 2010 May; 59(5):1117-25. PubMed ID: 20427697
    [No Abstract]   [Full Text] [Related]  

  • 79. Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.
    Tura A; Bagger JI; Ferrannini E; Holst JJ; Knop FK; Vilsbøll T; Mari A
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1123-1129. PubMed ID: 29162361
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.
    Lund A; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
    Am J Physiol Endocrinol Metab; 2011 Jun; 300(6):E1038-46. PubMed ID: 21386059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.